See more : TOMI Environmental Solutions, Inc. (TOMZ) Income Statement Analysis – Financial Results
Complete financial analysis of Avid Bioservices, Inc. (CDMO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Avid Bioservices, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Reliance Global Group, Inc. (RELI) Income Statement Analysis – Financial Results
- Medical Care Technologies Inc. (MDCE) Income Statement Analysis – Financial Results
- PSP Swiss Property AG (PSPSF) Income Statement Analysis – Financial Results
- Qt Group Oyj (QTCOM.HE) Income Statement Analysis – Financial Results
- C&D International Investment Group Limited (1908.HK) Income Statement Analysis – Financial Results
Avid Bioservices, Inc. (CDMO)
About Avid Bioservices, Inc.
Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. The company produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. It also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, testing, and characterization. The company serves biotechnology and biopharmaceutical industries. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is headquartered in Tustin, California.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 139.91M | 149.27M | 119.60M | 95.87M | 59.70M | 53.60M | 53.62M | 57.63M | 44.69M | 26.78M | 22.40M | 21.68M | 15.23M | 13.49M | 27.94M | 18.15M | 6.09M | 3.71M | 3.19M | 4.96M | 3.31M | 3.92M | 3.77M | 979.00K | 1.00K | 100.00K | 500.00K | 300.00K | 3.10M | 100.00K |
| Cost of Revenue | 132.59M | 117.79M | 82.95M | 66.56M | 55.77M | 46.38M | 56.55M | 38.26M | 22.97M | 15.59M | 13.11M | 12.60M | 10.15M | 7.30M | 8.72M | 9.06M | 4.80M | 3.30M | 3.30M | 4.40M | 2.21M | 2.86M | 0.00 | -412.00K | -516.00K | 3.50M | -700.00K | -300.00K | 0.00 | 1.00M |
| Gross Profit | 7.32M | 31.48M | 36.65M | 29.31M | 3.93M | 7.22M | -2.92M | 19.37M | 21.72M | 11.19M | 9.29M | 9.09M | 5.08M | 6.20M | 19.23M | 9.09M | 1.29M | 412.00K | -104.00K | 558.00K | 1.10M | 1.06M | 3.77M | 1.39M | 517.00K | -3.40M | 1.20M | 600.00K | 3.10M | -900.00K |
| Gross Profit Ratio | 5.23% | 21.09% | 30.64% | 30.57% | 6.59% | 13.48% | -5.45% | 33.61% | 48.61% | 41.78% | 41.48% | 41.91% | 33.35% | 45.92% | 68.81% | 50.06% | 21.16% | 11.11% | -3.26% | 11.25% | 33.25% | 27.06% | 100.00% | 142.08% | 51,700.00% | -3,400.00% | 240.00% | 200.00% | 100.00% | -900.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 28.30M | 59.53M | 43.00M | 27.72M | 24.31M | 35.69M | 29.46M | 24.66M | 18.42M | 18.28M | 15.88M | 12.42M | 11.16M | 9.67M | 8.74M | 13.51M | 7.38M | 8.08M | 8.80M | 7.60M | 30.00M | 1.70M | 0.00 |
| General & Administrative | 25.20M | 27.18M | 20.63M | 16.76M | 14.32M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.48M | 3.81M | 4.24M | 6.20M | 4.50M | 3.30M | 900.00K | 700.00K |
| Selling & Marketing | 800.00K | 700.00K | 600.00K | 300.00K | 200.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 26.00M | 27.88M | 21.23M | 17.06M | 14.52M | 12.85M | 16.46M | 19.33M | 18.55M | 18.69M | 17.27M | 13.13M | 11.46M | 11.42M | 8.18M | 6.98M | 7.15M | 6.45M | 6.56M | 5.10M | 4.23M | 2.99M | 2.48M | 3.81M | 4.24M | 6.20M | 4.50M | 3.30M | 900.00K | 700.00K |
| Other Expenses | 1.00 | 1.00M | -81.00K | 133.00K | 355.00K | 0.00 | 1.26M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 412.00K | 516.00K | 1.00M | 700.00K | 300.00K | 200.00K | 200.00K |
| Operating Expenses | 26.00M | 27.88M | 21.23M | 17.06M | 14.52M | 12.85M | 16.46M | 47.63M | 78.08M | 61.69M | 45.00M | 37.44M | 47.15M | 40.88M | 32.84M | 25.40M | 25.43M | 22.32M | 18.98M | 16.26M | 13.90M | 11.73M | 15.98M | 11.60M | 12.83M | 16.00M | 12.80M | 33.60M | 2.80M | 900.00K |
| Cost & Expenses | 158.59M | 145.67M | 104.18M | 83.63M | 70.29M | 59.23M | 73.00M | 85.89M | 101.05M | 77.28M | 58.11M | 50.04M | 57.30M | 48.18M | 41.56M | 34.47M | 30.23M | 25.62M | 22.28M | 20.66M | 16.11M | 14.59M | 15.98M | 11.19M | 12.31M | 19.50M | 12.10M | 33.30M | 2.80M | 1.90M |
| Interest Income | 0.00 | 2.60M | 2.68M | 133.00K | 474.00K | 282.00K | 102.00K | 108.00K | 722.00K | 142.00K | 349.00K | 322.00K | 41.00K | 1.05M | 116.00K | 200.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 4.34M | 2.60M | 2.68M | 1.16M | 8.00K | 11.00K | 27.00K | 7.00K | 14.00K | 1.00K | 5.00K | 54.00K | 90.00K | 516.00K | 997.00K | 408.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 11.11M | 7.21M | 4.48M | 3.45M | 3.09M | 2.75M | 2.56M | 2.46M | 1.54M | 1.04M | 986.00K | 1.09M | 908.00K | 652.00K | 1.12M | 503.00K | 486.00K | 866.00K | 415.00K | 325.00K | 2.19M | 1.38M | 424.00K | 412.00K | 516.00K | 1.00M | 700.00K | 300.00K | 200.00K | 200.00K |
| EBITDA | -11.48M | 10.91M | 19.90M | 15.70M | -7.38M | -2.59M | -16.82M | 3.76M | 5.02M | -49.32M | -34.37M | -28.64M | -41.12M | -32.98M | -13.05M | -15.61M | -23.65M | -21.04M | -18.67M | -15.38M | -10.61M | -9.29M | -11.79M | -9.80M | -11.79M | -18.50M | -11.30M | -32.90M | 500.00K | -1.60M |
| EBITDA Ratio | -8.21% | 3.08% | 12.83% | 12.91% | -17.14% | -10.49% | -35.95% | -48.85% | -121.07% | -184.15% | -153.44% | -129.27% | -276.18% | -257.09% | -44.72% | -87.12% | -388.22% | -567.53% | -623.14% | -310.12% | -320.19% | -236.90% | -313.17% | -1,000.20% | -960,400.00% | -18,800.00% | -2,180.00% | -10,900.00% | 22.58% | 3,400.00% |
| Operating Income | -18.68M | -2.61M | 10.86M | 8.92M | -10.59M | -5.62M | -20.64M | -28.26M | -56.36M | -50.50M | -35.71M | -28.35M | -42.07M | -34.69M | -13.61M | -16.32M | -24.14M | -21.91M | -19.08M | -15.70M | -12.80M | -10.67M | -12.22M | -10.21M | -12.31M | -19.40M | -11.60M | -33.00M | 300.00K | -1.80M |
| Operating Income Ratio | -13.35% | -1.75% | 9.08% | 9.31% | -17.73% | -10.49% | -38.49% | -49.04% | -126.12% | -188.56% | -159.39% | -130.76% | -276.18% | -257.09% | -48.72% | -89.89% | -396.19% | -590.88% | -597.65% | -316.68% | -386.12% | -272.12% | -324.43% | -1,043.21% | -1,231,000.00% | -19,400.00% | -2,320.00% | -11,000.00% | 9.68% | -1,800.00% |
| Total Other Income/Expenses | -8.25M | -2.01M | -2.76M | -1.03M | 119.00K | 282.00K | 75.00K | 101.00K | 708.00K | 141.00K | 344.00K | -1.43M | -49.00K | 536.00K | 13.61M | 16.32M | 964.00K | 1.11M | 2.02M | 252.00K | -1.55M | 0.00 | 0.00 | -9.00K | -2.19M | 499.00K | 0.00 | 0.00 | -200.00K | -5.00M |
| Income Before Tax | -26.93M | 2.00M | 12.66M | 11.21M | -10.47M | -5.34M | -20.56M | -28.16M | -55.65M | -50.36M | -35.36M | -29.78M | -34,151.00B | -34,151.00B | -14,494.00B | -16,524.00B | 0.00 | 0.00 | -17.85M | 0.00 | -14.35M | 0.00 | 0.00 | -10.22M | -14.50M | -19.00M | 0.00 | 0.00 | 100.00K | -6.80M |
| Income Before Tax Ratio | -19.25% | 1.34% | 10.59% | 11.70% | -17.53% | -9.96% | -38.35% | -48.86% | -124.54% | -188.04% | -157.86% | -137.34% | -224,190,901.33% | -253,120,367.63% | -51,869,877.97% | -91,036,306.54% | 0.00% | 0.00% | -559.16% | 0.00% | -432.86% | 0.00% | 0.00% | -1,044.13% | -1,450,000.00% | -19,000.00% | 0.00% | 0.00% | 3.23% | -6,800.00% |
| Income Tax Expense | 113.83M | 1.44M | -115.01M | -2.29M | -3.21M | -284.00K | -1.29M | -2.36M | 722.00K | 142.00K | 349.00K | -1.03M | 536.00B | 536.00B | -881.00B | -208.00B | -964.00K | -1.11M | -2.02M | -252.00K | 0.00 | 889.00K | -500.00K | -678.00K | 2.20M | 100.00K | 200.00K | 200.00K | 0.00 | 5.10M |
| Net Income | -140.75M | 560.00K | 127.67M | 11.21M | -7.26M | -4.22M | -21.81M | -28.16M | -55.65M | -50.36M | -35.36M | -29.78M | -42.12M | -34.15M | -14.49M | -16.52M | -23.18M | -20.80M | -17.06M | -15.45M | -14.35M | -11.56M | -11.72M | -9.54M | -14.51M | -19.50M | -11.80M | -33.20M | 300.00K | -6.90M |
| Net Income Ratio | -100.60% | 0.38% | 106.75% | 11.70% | -12.15% | -7.86% | -40.68% | -48.86% | -124.54% | -188.04% | -157.86% | -137.34% | -276.50% | -253.12% | -51.87% | -91.04% | -380.37% | -560.84% | -534.33% | -311.60% | -432.86% | -294.80% | -311.15% | -973.95% | -1,451,400.00% | -19,500.00% | -2,360.00% | -11,066.67% | 9.68% | -6,900.00% |
| EPS | -2.23 | 0.01 | 2.08 | 0.06 | -0.13 | -0.08 | -0.46 | -0.76 | -1.80 | -1.93 | -1.53 | -1.73 | -3.53 | -3.93 | -2.07 | -2.56 | -3.67 | -3.79 | -3.55 | -3.73 | -3.74 | -3.47 | -3.92 | -3.51 | -6.26 | -10.32 | -13.35 | -54.25 | 0.70 | -15.40 |
| EPS Diluted | -2.23 | 0.01 | 1.81 | 0.06 | -0.13 | -0.08 | -0.46 | -0.76 | -1.80 | -1.93 | -1.53 | -1.73 | -3.53 | -3.93 | -2.07 | -2.56 | -3.67 | -3.79 | -3.55 | -3.73 | -3.74 | -3.47 | -3.92 | -3.51 | -6.26 | -10.32 | -13.35 | -54.25 | 0.70 | -15.40 |
| Weighted Avg Shares Out | 63.20M | 62.27M | 61.48M | 58.22M | 56.33M | 55.98M | 47.06M | 37.11M | 30.90M | 26.08M | 23.08M | 17.20M | 11.94M | 8.70M | 7.01M | 6.46M | 6.32M | 5.49M | 4.81M | 4.14M | 3.84M | 3.33M | 2.99M | 2.72M | 2.32M | 1.89M | 884.22K | 611.98K | 428.57K | 448.05K |
| Weighted Avg Shares Out (Dil) | 63.20M | 63.78M | 70.47M | 59.43M | 56.33M | 55.98M | 47.06M | 37.11M | 30.90M | 26.08M | 23.08M | 17.20M | 11.94M | 8.70M | 7.01M | 6.46M | 6.32M | 5.49M | 4.81M | 4.14M | 3.84M | 3.33M | 2.99M | 2.72M | 2.32M | 1.89M | 884.22K | 611.98K | 428.57K | 448.05K |
Avid Bioservices, Inc. (CDMO) Q3 2024 Earnings Call Transcript
Avid Bioservices, Inc. (NASDAQ:CDMO ) Q3 2024 Earnings Conference Call April 29, 2024 4:30 PM ET Company Participants Tim Brons – Investors Relations Group Nick Green – President and Chief Executive Officer Dan Hart – Chief Financial Officer Matt Kwietniak...
Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024
-- Recorded Third Quarter Revenue of $33.8 Million -- -- Signed $41 Million in Net New Business Resulting in Record High Backlog of $206 Million --
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Avid Bioservices, Inc. - CDMO
NEW YORK , April 12, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Avid Bioservices, Inc. ("Avid" or the "Company") (NASDAQ: CDMO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Avid Bioservices, Inc. - CDMO
NEW YORK , April 4, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Avid Bioservices, Inc. ("Avid" or the "Company") (NASDAQ: CDMO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Avid Bioservices, Inc. - CDMO
NEW YORK , March 27, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Avid Bioservices, Inc. ("Avid" or the "Company") (NASDAQ: CDMO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Global Contract Development and Manufacturing Organization Market Analysis Report 2023-2024 and 2029: Flexible and Scalable Manufacturing Processes Shaping the CDMO Landscape – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Contract Development and Manufacturing Organization Market: Analysis By Type, By Product, By Sourcing, By Application, By Region, Size and Trends with Impact of COVID-19 and Forecast up to 2029” report has been added to ResearchAndMarkets.com’s offering. The...
Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q
TUSTIN, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (Nasdaq:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO), announced today it received a notice (the “Notice”) on March 19, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”)...
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Avid Bioservices, Inc. (CDMO) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Avid Bioservices, Inc. (“Avid” or the “Company”) (NASDAQ: CDMO) investors concerning the Company's possible...
Avid Bioservices, Inc. (CDMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
NEW YORK--(BUSINESS WIRE)---- $CDMO #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Avid Bioservices, Inc. (“Avid Bioservices” or “the Company”) (NASDAQ: CDMO). Investors who purchased Avid Bioservices securities are encouraged to obtain additional...
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Avid Bioservices, Inc. (CDMO) on Behalf of Investors
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Avid Bioservices, Inc. (“Avid” or the “Company”) (NASDAQ: CDMO) investors concerning the Company's possible violations of federal securities laws. On March 6, 2024, Avid disclosed that...
Source: https://incomestatements.info
Category: Stock Reports